27 results about "Systemic disease" patented technology

The invention discloses a method and system for screening drug targets with space-time specificity and computer equipment, and relates to the technical field of bioinformatics and computational biology. The screening method is based on single cell transcriptome sequencing data, and comprises the following steps: (1) quantitatively reconstructing spatial positioning and functional modes of cells in tissues, namely 1.1) carrying out data preprocessing on the single cell transcriptome sequencing data; 1.2) reconstructing the spatial positioning of the single cell; 1.3) reconstructing a single cell biological function mode; (2) screening a drug target with space-time specificity, wherein the screening comprises the following steps: 2.1) cell-cell communication analysis; the invention discloses a single-cell data analysis method based on a GRN (Gene Regulatory Network), which is characterized by comprising the following steps of (1) establishing a single-cell data analysis method, (2) establishing a GRN (Gene Regulatory Network) taking a specific tissue microenvironment state as a core, and (3) discovering a target spot. The single-cell data analysis method is innovative, provides a new thought and a technical path for research and development of drugs for metabolic diseases and other systemic diseases, and has a popularization and application basis.

The invention discloses a magnetoelectric stent for realizing bone repair under external field driving and a preparation method and application thereof.The stent comprises a stent body based on a triple-period minimal curved surface structure and a magnetoelectric nano-particle coating, and the stent body comprises a convoluted and / or through hole structure; and the magnetoelectric nanoparticle coating is loaded on the inner surface of at least part of the pore structure. The magnetoelectric stent is suitable for providing better mechanical support for the early stage of bone repair of large-area bone defects, meanwhile, under the synergistic effect of magnetoelectric stimulation, osteogenesis and angiogenesis coupling can be promoted, and bone defect repair under the complex conditions of oral clinical alveolar bone vertical bone increment and systemic diseases such as inflammation and the like is achieved.

The invention discloses a dynamic trajectory construction and visual mapping method for association of mental disorder brain network damage and systemic system diseases, and belongs to the field of artificial intelligence medical application. According to the method, high-resolution MRI images, biomarkers and clinical information of major mental disorder patients are collected, and the influence of factors such as age, gender, medication and diagnosis on the braingut axis and the cardio-cerebral axis is evaluated through multi-modal data fusion. By constructing a disease dynamic trajectory model, brain structures and function change modes corresponding to different mental disorders are identified. Large-scale samples are analyzed through machine learning, potential risks and protection factors are extracted, and a visual tool is developed to visually display changes of the brain under different disease systems. A closed-loop feedback mechanism is established through follow-up visit, the disease progress and the intervention effect are dynamically tracked, and key evaluation indexes are identified. According to the invention, theoretical basis and practical guidance are provided for early screening, precise intervention and personalized treatment of mental disorders, and the diagnosis and treatment accuracy and efficiency are remarkably improved.

The invention relates to CD1a-reactive T-cell receptors (TCRs), and their use in treating or preventing an inflammatory skin or mucosal disorder or disease or one or more associated systemic disease or disorder, one or more inflammatory drug reaction which manifests systemically, a CD1a-expressing malignancy or a malignancy wherein CD1a is altered in expression or function.

Disclosed herein are methods, devices and kits suitable for high throughput screenings of extracellular pyridine nucleotide levels, such as NAD+ levels which are suitable for monitoring pyridine nucleotide induced slowdown of not only pathogenesis of multiple systemic diseases but also aging. In particular, assaying methods quantifying extracellular pyridine nucleotide(s), such as NAD+, in the low micromolar to the low nanomolar range in a sample that may have been subjected to long term storage are disclosed using a two-step enzymatic cycling reaction employing an oxidoreductase such as alcohol dehydrogenase. A modified revised simulated body fluid is also disclosed that is employed as a standard matrix to optimise enzymatic activity, linearity and / or sensitivity of the methods, devices and kits.

This invention provides an antibody fusion protein comprising a binding construct that targets and is capable of binding to Ang-2, IL-6 receptors, and at least one VEGF family member; or an antigen-binding fragment or domain of the antibody fusion protein. The antibody fusion protein comprises an antibody or binding peptide against Ang-2, an antibody against IL-6R, and multiple extracellular domains of the VEGF receptor as binding components. The antibody fusion protein is suitable for treating or controlling ocular or systemic diseases, symptoms, or conditions caused by abnormal angiogenesis, increased vascular leakage, or inflammation.

The invention discloses a nutrition regulation and control method for disease resistance of kiwi fruits, a germination fertilizer and a preparation method, and the preparation method comprises the following steps: constructing a ternary interaction system consisting of a sulfur source, succinic acid and Pseudomonas fluorescens, and applying the ternary interaction system to rhizosphere nutrition management of the kiwi fruits in early spring. And three-dimensional coupling of nutrition supply, signal activation and microbial regulation and control is synchronously realized in the rhizosphere microdomain. Meanwhile, lignin monomer synthesis is continuously activated and promoted through a salicylic acid signal channel, high-activity laccase serves as a key enzyme for lignin monomer polymerization, lignin monomer polymerization reaction is accelerated, synthesis and deposition of lignin in plant cell walls are promoted, plant endogenous disease-resistant signal cascade is continuously amplified, and plant disease resistance is improved. The kiwi fruits are induced to generate stable systematic disease resistance. The composition can prevent and control diseases for a long time and cooperatively promote plant growth.

The present application relates to the technical field of biological medicine, in particular to a Mongolian medicine composition with curative effect on liver disease based on data mining. National medicine has hundreds of years of clinical experience, can treat systemic diseases, and has definite curative effect. And its multi-component acts on multi-target, with small toxic and side effects. Through collating, summarizing and concluding the prescriptions recorded in Mongolian Medicine Prescriptions for treating liver disease, the use characteristics and compatibility rules of Mongolian medicine for treating liver disease are analyzed. The Mongolian medicine composition comprises safflower 180 parts, gardenia 60 parts, chebula 60 parts and five spirit resins 60 parts. The present application realizes efficient, systematic and low-toxic treatment of liver disease through the synergistic regulation mechanism of multi-component and multi-target, has obvious comprehensive advantages of liver protection, anti-inflammatory and anti-fibrosis and promotion of hepatocyte repair, fills the blank of multi-target traditional Chinese medicine combination scheme in the existing liver disease treatment field, and has important clinical popularization value and application prospect.

The present invention refers to micro-fragmented fat or a composition comprising micro-fragmented fat for use in the treatment of a systemic disease, preferably associated to or caused by sepsis. Moreover, the micro-fragmented fat or the composition comprising micro-fragmented fat is used for treating a systemic, inflammatory, immune, or chronic disease, said disease being intended as a consequence of septic disease. Preferably, the micro-fragmented fat is useful for treating both the acute (early) and late stages of sepsis.

The present invention provides systems and methods for the detection of systemic disease from bacterial content samples obtained from a subject. Also provided are methods of training a machine learning algorithm to correlate patient microbiome sequence data with a disease state or disease development risk. These systems and methods utilize a high-resolution, database-independent, high-throughput microbial profiling platform to diagnose systemic disease in patients or to identify those patients at risk of developing systemic disease. Also provided are systems and kits for carrying out the methods.

The application discloses a kind of early warning method and device of children's eye disease and systemic genetic syndrome, it is related to ophthalmic examination equipment technical field.The method includes: collection ocular anterior segment image data set, utilize the multi-task segmentation model after training, obtain multiple congenital eye disease quantitative feature data, then based on the risk index calculator of pre-established index calculation is carried out, and the congenital eye disease risk index is obtained, classification processing is carried out, matches eye abnormal phenotype, and obtains systemic disease early warning report.The application can realize more than 10 kinds of congenital eye disease and rare but important lesion in one examination screening, and simultaneously establishes the intelligent early warning system of eye phenotype and systemic genetic syndrome.

The application discloses a screening method and system of a drug target with space-time specificity and a computer device, and relates to the technical field of bioinformatics and computational biology. The screening method is based on single-cell transcriptome sequencing data, and the method comprises the following steps: (1) quantitatively reconstructing the spatial positioning and functional mode of cells in a tissue, which comprises the following steps: 1.1) performing data preprocessing on the single-cell transcriptome sequencing data; 1.2) reconstructing the spatial positioning of single cells; and 1.3) reconstructing the biological functional mode of single cells; and (2) screening a drug target with space-time specificity, which comprises the following steps: 2.1) analyzing cell-cell communication; 2.2) constructing a gene regulatory network (GRN) with a specific tissue microenvironment state as the core; and 2.3) discovering a target. The application verifies an innovative single-cell data analysis method, and provides a new thought and technical path for drug research and development of metabolic diseases and other systemic diseases, and has the basis of popularization and application.

The present invention provides systems and methods for the detection of systemic disease from bacterial content samples, such as for example gut microbiome samples, obtained from a subject. Also provided are methods of training a machine learning algorithm to correlate patient microbiome sequence data with a disease state or disease development risk. These systems and methods utilize a high-resolution, database-independent, high-throughput microbial profiling platform to diagnose systemic disease in patients or to identify those patients at risk of developing systemic disease. Also provided are systems and kits for carrying out the methods.

A fusion protein comprises two VEGF-binding units, a least one of which comprises at least an extracellular domain of at least a VEGF receptor. The other VEGF-binding unit can comprise a VEGF-C antibody or at least a different extracellular domain of at least a VEGF receptor. The fusion protein can further comprise an Ang-2-binding unit. The fusion protein is useful in treating or controlling an ocular or systemic disease, condition, or disorder that has etiology in at least one of aberrant angiogenesis, increased vascular leakage, and inflammation.

A fusion protein, or an antigen-binding fragment, or antigen-binding domain thereof comprises a binding construct targeting and being capable of binding Ang-2, IL-6, and at least one of the VEGF family members. The fusion protein comprises, as binding components, an antibody or binding polypeptide directed against Ang-2, an antibody directed against IL-6, and a plurality of extracellular domains of VEGF receptors. The fusion protein is useful in treating or controlling an ocular or systemic disease, condition, or disorder that has etiology in one of aberrant, excessive angiogenesis, increased vascular leakage, and inflammation.

The invention discloses a magnetoelectric stent for realizing bone repair under external field driving and a preparation method and application thereof.The stent comprises a stent body based on a triple-period minimal curved surface structure and a magnetoelectric nano-particle coating, and the stent body comprises a convoluted and / or through hole structure; and the magnetoelectric nanoparticle coating is loaded on the inner surface of at least part of the pore structure. The magnetoelectric stent is suitable for providing better mechanical support for the early stage of bone repair of large-area bone defects, meanwhile, under the synergistic effect of magnetoelectric stimulation, osteogenesis and angiogenesis coupling can be promoted, and bone defect repair under the complex conditions of oral clinical alveolar bone vertical bone increment and systemic diseases such as inflammation and the like is achieved.

This application discloses a multispecific fusion protein comprising a binding construct that targets and is capable of binding to at least one of DLL4 and VEGF family members; or an antigen-binding fragment or domain thereof. This application also discloses a multispecific fusion protein comprising an antibody against DLL4 or an antigen-binding fragment thereof, multiple extracellular domains of the VEGF receptor or an antibody against at least one VEGF family member or an antigen-binding fragment thereof, and an antibody or binding peptide against Ang-2. The multispecific fusion protein can be used to treat or control ocular or systemic diseases, conditions, or disorders caused by abnormal angiogenesis, increased vascular leakage, inflammation, fibrosis, or combinations thereof.

This document describes the use of the CRB1 gene in the preparation of drugs for treating systemic diseases such as eye and intestinal disorders. It also describes the use of CRB1 gene-based therapeutics in the preparation of drugs for treating systemic diseases such as eye and intestinal disorders.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors: e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body. e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.

The invention discloses a high-throughput and high-sensitivity screening method for endogenous itching-causing substances and application of the high-throughput and high-sensitivity screening method. According to the invention, firstly, endogenous itching-causing substances are screened out through a metabonomics technology, and then are verified through combination of a NanoBiT-based MRGPR detection system and an in-vivo experiment, so that integrated screening of the endogenous itching-causing substances in systemic disease itching is realized, and the defects of single discovery and screening mode of pruritus in systemic disease itching at present, low screening efficiency and the like are overcome. And breakthrough progress is not made yet. A cholestatic pruritus mouse is taken as an object, and the endogenous substance LPC (18: 1) screened from the cholestatic pruritus disease has strong activation and selectivity of the Mrgpra1 pruritus receptor, and can be used as an Mrgpra1 pruritus receptor agonist tool molecule for screening a tool medicine taking the Mrgpra1 pruritus receptor as a target spot.

The present invention relates to a mixture, compositions containing said mixture, and the use thereof in the treatment and / or prevention of correct peripheral nervous system function, for counteracting and / or treating peripheral neuropathies and neuropathic pain, caused by caused by compression, metabolic imbalances, pathogens, toxic agents, drugs, systemic inflammatory diseases and genetic systemic diseases. In greater detail, the present invention refers to a mixture comprising or, alternatively, consisting of: i) an extract of turmeric and / or one or more of its active ingredients; ii) L-acetyl carnitine and / or a salt thereof; iii) a bergamot extract and / or one or more of its active ingredients; preferably belonging to the flavonoid category, wherein said mixture is for use in a method for the prevention or treatment of peripheral neuropathies and neuropathic pain.

This invention provides a systemic feline calicivirus (FCV) yolk antibody, its preparation method, and its application. The yolk antibody is prepared using a novel, highly pathogenic FCV strain, CC475, whose cDNA sequence is shown in SEQ ID NO.1. This strain belongs to the VS-FCV strain, which causes fatal systemic disease in cats. It has low homology with classic feline caliciviruses. The yolk antibody prepared using this VS-FCV strain exhibits high titer, good stability, and rapid efficacy, and can be used for rapid treatment or emergency prevention of systemic feline calicivirus infection with a high protection rate.

The present invention provides a formulation for use in the treatment of systemic and ophthalmic diseases associated with elevated retinal venous pressure. [Solution] A formulation containing at least one folic acid (folate) is provided.

An apparatus and method are used to deliver an electrical current to, through or across gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, cosmetic, and or regenerative benefits. These benefits include killing or modifying oral microbes, increasing oral vasodilation, reducing oral biofilm, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, periodontitis, and oral malodor, and other systemic diseases correlated with oral pathogens. Use of systems and methods according to the present invention may effectively tighten epithelial contact with one or more teeth (e.g., by the junctional epithelium and / or the sulcular epithelium) and / or cause a tightening of the oral epithelium, thereby improving an appearance of a human smile.

The application relates to a fundus photograph-based method, system and device for calculating the diameters of retinal blood vessels. The method comprises the following steps: acquiring a fundus photograph to be processed; segmenting the fundus photograph to be processed to obtain a fundus photograph with a tree structure and single-branch blood vessels; calculating the normal vector of each branch blood vessel segment pixel by pixel; and through nonlinear interpolation and smoothing processing, the average, maximum and minimum diameters of each branch blood vessel are obtained. The method aims to extract a target region based on an automatic segmentation algorithm, then traverse each branch blood vessel according to the tree structure to calculate the normal vector, and then calculate the parameters of each branch blood vessel through interpolation operation, so that the important clinical significance and potential application value of the method in the prediction and analysis of cardiovascular diseases and systemic diseases are discovered.

The present invention relates to antibodies or antigen-binding fragments thereof capable of binding to CD1a. The antibodies or antigen-binding fragments thereof may be chimeric or humanized and may be used to treat one or more inflammatory skin or mucosal disorders or diseases, or one or more related systemic diseases or disorders, or one or more inflammatory drug reactions manifesting systemically, or CD1a-expressing malignancies.